Dyspepsia affects an estimated 15 to 25 per cent of Malaysians, making it one of the most common gastrointestinal complaints nationwide.

Hematochezia was the most common symptom in patients with AAV and GI manifestations, and other symptoms included abdominal pain, fever, diarrhea, and vomiting.

The FDA has approved nivolumab (Opdivo) plus doxorubicin, vinblastine, and dacarbazine (AVD) for the treatment of adult and pediatric patients age 12 and older with treatment-naiv ...